Drug Trial Radar · NCT07153757
De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2,934
Planned (sponsor's estimate)
Start
Sep 1, 2025
Primary completion
Sep 1, 2033
Study completion Sep 1, 2033
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective, randomized, open-label, non-inferiority Phase III clinical trial, planning to enroll 2,934 patients, with a 1:1 allocation to either the conventional endocrine therapy group or the de-escalation therapy group. The aim is to evaluate the safety and efficacy of 2-3 years of de-escalated endocrine therapy in patients with T1N0M0 potentially low-risk breast cancer, respectively.
Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Endocrine Therapy of Physician's ChoiceDrug
This study employs a 2-3 year de-escalated endocrine therapy regimen in the experimental group, which distinguishes it from other escalation therapy studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-year disease-free survival in the per-protocol populationTime frame: 5 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
270 Dongan Road, Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.